| Objective:To compare the clinical efficacy and safety of DEB-TACE and cTACE in the treatment of advanced primary liver cancer.Methods:The data of a total of 76 cases of middle-late stage of primary liver cancer patients in the hospital with conventional treatment(January 2018-December 2020)were retrospectively collected and analyzed,and then,by using the method of propensity score matching each in 23 patients in both groups,compared two groups of patients before and 3 days and a month after treatment the change of liver function.Results were evaluated at 1,3,and 6 months after each intervention.And the incidence of postoperative adverse reactions and complications of the two groups were recorded,so as to compare the treatment effect and safety of the two groups.Results: The median progression-free survival was 7 months(95%CI:5.884-11.012)and6 months(95%CI:5.349-8.077),and the median overall survival was 14 months(95%CI:12.054-18.233)and 11 months(95%CI:9.243-13.348),respectively,in the cTACE and DEB-TACE groups.According to m RECIST criteria,the objective response rate(CR+PR)of DEB-TACE group at 1,3 and 6 months were 65.2%,52.2% and 47.8%,respectively and in the c TACE group were 87.0%,65.2% and 47.8%,respectively.The disease control rate(CR+PR+SD)at 1,3 and 6 months in the DEB-TACE group were82.6%,78.3% and 73.9%,respectively and in the cTACE group were 91.3%,82.6% and73.9%,respectively,without statistical significance(P>0.05).There was no significant difference in liver function indexes before and 3 days and 1 month after interventional therapy between the two groups(P>0.05).There was no significant difference in the incidence of post-embolization syndrome between the two groups(P>0.05),and no serious adverse reactions occurred.Conclusion :There is no significant difference between DEB-TACE and c TACE in the treatment of patients with advanced primary liver cancer,and there is no significant difference in adverse drug reactions. |
PDF Full Text Request